SUPPLY ISSUE Octreotide DBL Injection All strengths
Further to our notification of 16 December 2019.
Click here to read the supplier notification regarding the above mentioned product. Interim measures are being implemented as supply is not expected to be back until end-September 2020.
ProPharma / PWR have again been proactive and have set in place an allocation of 1 per customer per week on all remaining DBL Octreotide stock held, which is limited.
Once sold we will need switch to alternative S29 products for Pharmacode 2272822 and 2272806.
Please note as with all Section 29 products we are not able to accept credit returns, so please order with care.
Pharmacode 2272815 will be constrained (supply controlled) by Pfizer.
We accept one size does not fit all, but in these instances where very little if any notice is provided we need to act on what stock remains available in the supply chain.
If you feel this unduly impacts on what your pharmacy requires or needs then you MUST discuss this with your Branch Manager or Key Account Manager.
Our Customer Services Team DO NOT have the authority to change allocation levels.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.